Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. Big 3 Look for New Indian Drug Suppliers (India)

This article was originally published in PharmAsia News

Executive Summary

Large U.S. drug wholesalers plan to outsource their requirements from upcoming Indian manufacturers, a move that will provide competition to such leading Indian drug manufacturers as Ranbaxy, Dr Reddy's, Sun Pharma, Lupin and Zydus Cadila, who have benefited tremendously from sales in the U.S. market. At least ten tier-II and tier -III Indian pharmaceutical companies with plants in Mumbai, Ahmedabad, and Hyderabad that are approved, or may be approved by the U.S. FDA, are reportedly on the radar of distributors McKesson Corporation, Cardinal Health, and AmerisourceBergen. These three wholesalers control nearly all the entire drug distribution market in the U.S. McKesson and Cardinal Health have reportedly sent executives to India to assess the capabilities of these companies. "It is difficult for any Indian company to do business with the U.S. without the big three who control over 90 per cent of the US drug market," said Sujay Shetty, associate director, PricewaterhouseCoopers. "India has the maximum US FDA approved plants outside the US and it is natural for them to look at India for new opportunities." India has a share of approximately 23 percent in the total abbreviated new drug applications approvals and 48 percent of the drug master filings with the U.S. FDA. The United States is the largest generics market, with 28 percent of global generic sales. This is expected to hit $94 billion by 2010 and drugs worth $65-70 billion are going off-patent in the next 4-5 years, according to research reports by Crisil Research and SSKI Investment. The move by wholesalers is aimed at tapping cost-effective generic manufacturers directly, increasing the supply base across the world. (Click here for more

You may also be interested in...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

US FDA Reaffirms Commitment To Resuming Domestic Inspections As Industry Frustration Grows

Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.

‘Most Favored Nation’ Pricing Data May Be Long-Term Impact Of Last-Minute Rule

Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts